Montreal (ANTARA\/BUSINESS WIRE)- Medisca and EUROAPI have formed a\nstrategic partnership focused on expanding API access for pharmaceutical\ncompounding, creating differentiated access in North America and\nestablishing a broader framework for international growth and peptide\ncollaboration.<\/p>\n
Medisca and EUROAPI join forces to expand access to high-quality,\nEuropean-manufactured APIs for the compounding market.For more than\nthree decades, Medisca has built its business around the evolving needs\nof pharmaceutical compounders. That starts with the products it chooses\nto bring to market but extends much further to the manufacturers behind\nthem, the documentation and technical information supporting them, and\nthe quality systems that carry those products through to the\ncustomer.<\/p>\n
Share<\/p>\n
The partnership with EUROAPI advances that approach. Under the new\nstrategic partnership, Medisca becomes EUROAPI\u2019s first strategic\ndistribution partner focused on bringing its European-manufactured APIs\nto the North American compounding market. The collaboration includes\nexclusive supply arrangements for selected APIs and creates a framework\nto expand the offering over time, enter additional markets and advance\nnew areas of pharmaceutical innovation.<\/p>\n
For customers, the value goes beyond adding more APIs to a catalogue.\nThe partnership creates a stronger connection between manufacturing\nexpertise and the needs of the compounding market, supported by\ntechnical information, product documentation and Medisca\u2019s direct\ncustomer insight. This allows Medisca to respond more closely to what\ncompounders need today and continue adapting its offering as those needs\nchange.<\/p>\n
\u201cThis partnership marks an important milestone in the growth of\nMedisca,\u201d said Peng Li, Chief Business Officer at Medisca. \u201cEUROAPI\nbrings deep manufacturing and technical expertise, with a strong focus\non quality, green chemistry and sustainability. These strengths align\nwith the evolving needs of the compounding market as personalized\nmedicine continues to grow across telehealth, wellness and new areas of\npatient care. Together, we are expanding API access, building new\nopportunities across markets and advancing collaboration in peptides. We\nare proud to partner with EUROAPI and confident in the long-term\npotential of what we can build together.\u201d<\/p>\n
At the center of the partnership is a shared ambition to bring\npharmaceutical manufacturing expertise, technical rigor and a strong\nquality foundation closer to the evolving needs of the compounding\nindustry. Medisca\u2019s approach begins at the source, with the\nmanufacturer, the specifications and technical documentation behind an\nAPI and continues through the quality systems and controls that support\nit through to the customer. Through the partnership, EUROAPI will\nprovide available technical and regulatory information relating to the\nAPIs, strengthening the connection between manufacturing expertise and\nMedisca\u2019s quality infrastructure. EUROAPI\u2019s focus on green chemistry,\nand sustainability further supports Medisca\u2019s commitment to responsible\nsourcing and broader social impact.<\/p>\n
The relationship is also designed to grow. Medisca and EUROAPI intend\nto collaborate on customer initiatives, training and commercial\nactivities, while adding new APIs over time and evaluating opportunities\nacross additional markets.<\/p>\n
Advancing collaboration in peptides<\/p>\n
Peptides are an important area of strategic collaboration for Medisca\nand EUROAPI. As Medisca continues to expand its global peptide strategy\nfor pharmaceutical compounding and personalized medicine, the companies\nintend to explore opportunities that combine Medisca\u2019s market expertise\nwith EUROAPI\u2019s capabilities in complex API development and\nmanufacturing. The collaboration creates a foundation to advance their\nwork in peptides as the market continues to evolve.<\/p>\n
\u201cMedisca\u2019s depth of expertise in pharmaceutical compounding and its\nclose understanding of the market make it a strong strategic partner for\nEUROAPI,\u201d said Frederic Robert, Chief Commercial Officer at EUROAPI.\n\u201cThis relationship creates new opportunities to broaden access to our\nAPIs, expand our reach in the compounding market and develop our\ncollaboration in areas such as peptides. We see significant potential to\ngrow together over the long term.\u201d<\/p>\n
For Medisca, the partnership marks another step in its broader\nstrategy to strengthen its API offering through direct relationships\nwith pharmaceutical manufacturers, expand differentiated access for\ncustomers and build for the next generation of personalized\nmedicine.<\/p>\n
To explore EUROAPI-manufactured APIs available through Medisca, visit\nwww.medisca.com<\/p>\n
About Medisca<\/p>\n
Founded in 1989, Medisca is a leader in personalized medicine and\npharmaceutical supply chain solutions, with a vast portfolio of over\n2,000 products complemented by a library of 10,000+ proprietary and\ncustomized medication formulas, expertise and services in pharmaceutical\ncompounding, continuing healthcare education, and analytical testing.\nProviding finely-tuned solutions to diverse wellness sectors in numerous\nmarkets globally, Medisca is bridging the gaps in healthcare and\nempowering personalized wellness for all. For more information, visit\nwww.medisca.com and follow us on LinkedIn, Facebook, and YouTube.<\/p>\n
About EUROAPI<\/p>\n
EUROAPI is focused on reinventing active pharmaceutical ingredients\nto sustainably meet customers\u2019 and patients\u2019 needs around the world. We\nare a leading player with approximately 200 products in our portfolio,\noffering a large span of technologies while also developing innovative\nmolecules through our Contract Development and Manufacturing\nOrganization (CDMO) activities.<\/p>\n
With strong R&D capabilities and five manufacturing sites located\nin Europe, EUROAPI provides its clients with high-quality API solutions\nin more than 80 countries. Our 3000+ people are committed to building\ntogether the future of public health by advancing and securing access to\nessential active ingredients, at the core of the healthcare value chain.\nEUROAPI is listed on Euronext Paris: EAPI. Find out more at\nwww.euroapi.com and follow us on LinkedIn.<\/p>\n
Contacts<\/p>\n
Medisca Communicationscommunications@medisca.com<\/p>\n
1-800-665-6334<\/p>", "url": "https:\/\/jawawa.id\/newsitem\/medisca-and-euroapi-form-strategic-partnership-to-strengthen-api-access-for-pharmaceutical-compounding-1791449421", "image": "" }, "sponsor": "Okusi Associates", "sponsor_url": "https:\/\/okusiassociates.com" }